MedTrace Logo

A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma

NCT00887029 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2015-04-21

No results posted yet for this study

Summary

Hypothesis:

* H1: Efficacy of Duotrav will be superior to Xalacom at 24 hours post dosing when both medications are given in the morning
* H2: A significant proportion of patients will prefer dosing of once daily topical fixed combination therapy in the morning compared to evening dosing

Conditions

Interventions

DRUG

DuoTrav (travoprost-timolol ophthalmic drops)

topical ophthalmic drops instilled 1 drop daily

DRUG

Xalacom (latanoprost-timolol ophthalmic drops)

topical ophthalmic drops instilled 1 drop daily

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Ophthalmic Consultants Centres, Canada

    lead OTHER

Principal Investigators

  • David B Yan, MD · Ophthalmic Consultant Centres

  • Navroop Gill, OD · Ophthalmic Consultant Centres

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00887029 on ClinicalTrials.gov